Clinical Trial · NCT03335280

68Ga-citrate PET/MR Imaging for Glioma

Overview

This is a prospective, single center, open-label study in adult patients with presumed World Health Organization (WHO) grade 3 or 4 glioma who will be undergoing surgical resection as standard of care. In some cases, patients will have had biopsy. Study participants will undergo 68Ga-citrate Positron Emission Tomography / magnetic resonance (PET/MR) prior to surgery.

Sponsor

University of California, San Francisco

Contacts

Susan Chang, MD (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT03335280

Drug / Compound

citrate

Isotope(s):
Target(s):
  • Fe(II)
Ligand Class: Small Molecules
Chelator: citrate

Eligibility

Inclusion

  • Karnofsky performance status of \>= 60
  • World Health Organization (WHO) grade 3 or 4 glioma planning to undergo surgery

Exclusion

  • Contraindications to magnetic resonance (MR) imaging (e.g. pacemakers, metallic implants, etc.)
  • Contraindications to Positron Emission Tomography (PET) imaging (e.g. pregnant or breast-feeding woman)